Company Vision

Ready to Change Everything

RosVivo Therapeutics targets diseases with breakthrough therapies

 utilizing microRNA (miRNA) and small interfering-RNA (siRNA) drugs. We discovered key miRNAs are responsible for the onset and development of Type 2 Diabetes (T2D). In addition, these key miRNAs also lead to the onset of obesity, fatty acid liver disease, hyperlipidemia, and gastroparesis.

Remarkably, restoration of these miRNAs reverses these disease states.

Scroll to Top